GLP-1 Medications and Insulin Resistance: Why This Is the Real Story

The GLP-1 conversation is dominated by weight loss numbers. 15% with semaglutide. 20% with tirzepatide. Before-and-afters. The scale.

But if you ask an endocrinologist what's happening at the metabolic level — what's actually changing in the patient's biology — the answer often starts with insulin resistance, not the number on the scale.

Insulin resistance is the upstream driver of type 2 diabetes, metabolic syndrome, cardiovascular disease, and much of the inflammation that characterizes modern chronic disease. GLP-1 medications address it directly and powerfully. That's the less-told story.

What Is Insulin Resistance?

In a metabolically healthy person, insulin acts as a key. When blood glucose rises after a meal, the pancreas releases insulin. Insulin "unlocks" glucose uptake in muscle cells, fat cells, and the liver — clearing glucose from the bloodstream and normalizing blood sugar.

In insulin resistance, the locks have been jammed. Cells don't respond normally to insulin signals. The pancreas compensates by producing more insulin (hyperinsulinemia). For a while, this works — blood glucose stays relatively normal, but at the cost of high insulin levels.

Over time: - High insulin promotes fat storage (particularly visceral fat) - The pancreatic beta cells that produce insulin become exhausted - Blood glucose starts to rise (pre-diabetes, then type 2 diabetes) - Systemic inflammation accelerates - Cardiovascular risk compounds

The visceral fat that accumulates with insulin resistance is itself metabolically active — secreting inflammatory cytokines and free fatty acids that worsen insulin sensitivity further. It's a self-reinforcing loop.

How GLP-1 Medications Break the Loop

GLP-1 receptor agonists interrupt insulin resistance through multiple mechanisms:

1. Direct pancreatic effects GLP-1 receptors are highly expressed in pancreatic beta cells. GLP-1 agonists enhance glucose-stimulated insulin secretion (they cause the pancreas to release insulin more appropriately in response to glucose) while suppressing glucagon (which would otherwise raise blood glucose). This glucose-dependent mechanism is why GLP-1 medications don't cause hypoglycemia the way insulin does — they only amplify insulin secretion when blood glucose is elevated.

2. Hepatic insulin sensitivity GLP-1 medications reduce liver fat (hepatic steatosis) — directly through receptor effects on hepatocytes, and indirectly through weight loss. Less liver fat → less hepatic insulin resistance → better glucose regulation from the liver.

3. Weight loss → visceral fat reduction The most powerful way to improve peripheral insulin sensitivity is to reduce visceral fat. GLP-1-mediated weight loss preferentially reduces visceral adipose tissue (the metabolically dangerous fat around organs, not subcutaneous fat). As visceral fat falls, the inflammatory adipokines and free fatty acids that drive insulin resistance decrease substantially.

4. Reduced caloric intake Simply eating less — particularly fewer refined carbohydrates and ultra-processed foods — directly improves insulin sensitivity. The appetite suppression from GLP-1 therapy often drives dietary changes that improve insulin sensitivity independent of weight loss per se.

5. Central nervous system effects GLP-1 receptors in the hypothalamus and brainstem modulate glucose metabolism directly — separate from the peripheral effects. These central effects contribute to improved glycemic control through mechanisms still being elucidated.

What Happens to Lab Markers

Fasting insulin: Often the earliest marker to improve. Within 4-8 weeks of starting GLP-1 therapy, fasting insulin levels typically fall 15-30%, even before significant weight loss. This reflects direct improvements in insulin sensitivity.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance): Calculated from fasting glucose and fasting insulin. Normalized values suggest meaningful improvement in insulin sensitivity. Expect gradual improvement over 3-6 months of therapy.

HbA1c (3-month blood glucose average): Clinical trials consistently show GLP-1 medications lower HbA1c significantly — by 0.8-1.8% in patients with elevated baseline values. In patients with pre-diabetes (HbA1c 5.7-6.4%), semaglutide frequently normalizes HbA1c to the healthy range.

Fasting glucose: Reductions of 10-25 mg/dL are common over the course of GLP-1 treatment, reflecting both improved insulin sensitivity and reduced gluconeogenesis.

Triglycerides: Elevated triglycerides are a hallmark of insulin resistance (high insulin → high triglyceride production in the liver). Triglyceride reductions of 20-30% with GLP-1 therapy reflect direct improvement in the insulin resistance → hepatic triglyceride pathway.

The Diabetes Prevention Data

The SELECT trial followed over 17,000 patients with obesity and cardiovascular disease (but without diabetes) on weekly semaglutide. After 3.4 years:

• Semaglutide group: 0.9% developed type 2 diabetes
• Placebo group: 3.5% developed type 2 diabetes
• 73% relative risk reduction in new-onset diabetes

This is among the most powerful diabetes prevention data in medical literature. For patients with pre-diabetes and obesity — a population at substantial risk of diabetes progression — GLP-1 therapy represents a disease-modifying intervention.

Insulin Resistance and Body Composition

One connection frequently overlooked: insulin resistance drives the type of weight gain that makes weight loss harder.

High insulin levels directly promote lipogenesis (fat storage) and suppress lipolysis (fat breakdown). In insulin-resistant patients, fat burning is metabolically suppressed even in a caloric deficit. This is why many insulin-resistant individuals find weight loss extraordinarily difficult despite reducing calories.

As GLP-1 therapy improves insulin sensitivity, fat metabolism becomes more accessible. The metabolic environment shifts from fat-storing to fat-burning. This contributes to why GLP-1 medications are more effective for weight loss than simple caloric restriction — they're changing the underlying metabolic context, not just reducing intake.

Who Needs to Know Their Insulin Resistance Status?

If you're considering or currently on GLP-1 therapy, requesting a fasting insulin test (in addition to the standard fasting glucose) gives much more complete metabolic information. Most standard labs include:

• Fasting glucose: High = pre-diabetes/diabetes
• HbA1c: 3-month average
• HOMA-IR calculation: Requires fasting glucose + fasting insulin

Many patients with normal fasting glucose have elevated insulin (and thus insulin resistance) — they're compensating with high insulin to maintain normal glucose. These patients are early in the progression toward pre-diabetes and are at elevated cardiovascular and metabolic risk that isn't captured by glucose or HbA1c alone.

Marrow's lab panels include fasting insulin by default for patients where metabolic health is a stated goal.

The Takeaway

GLP-1 medications work better than anything we've had before for weight loss. But framing them purely as weight loss drugs misses the deeper biology. What they're doing is reversing the metabolic dysfunction — the insulin resistance, the visceral fat, the inflammatory metabolic state — that both drives weight gain and causes the downstream chronic disease.

Weight loss is a symptom of that reversal. The underlying metabolic normalization is the real story.